Table 1.

Baseline characteristics of included studies for meta-analysis

Study, year	Nation	Study design	Number of patients	Gender		Age (years)	Contrast media	Dose	Diagnostic
				Male	Female
Tamai 2005 [13]	Japan	prospective study	29	21	8	63.5±11.9	Iopamidol	100mL	Histopathologic examination
Wang 2023 [14]	China	retrospective study	65	37	28	56.82±6.7	Iohexol	80mL	Histopathologic examination
Wang 2021 [15]	China	retrospective study	105	55	50	53.55(13-81)	Ultravist	NA	Histopathologic examination
Ren 2015 [16]	China	retrospective study	46	29	17	58(31-79)	Ultravist	80mL-100mL	Histopathologic examination
Kim 2002 [17]	South Korea	retrospective study	110	78	32	56(22-79)	Iopamidol	120mL	Histopathologic examination
He 2015 [18]	China	retrospective study	41	21	20	40.6±4.6	Omnipaque	1.2mL/kg	Histopathologic examination
Xie 2016 [19]	China	retrospective study	82	42	40	53.0±13.6	Iopamiro	90mL	Histopathologic examination
Gentili 2020 [20]	Italy	retrospective study	46	NA	NA	NA	Iomeron	1.5mL/kg	Histopathologic examination
Jung 2012 [21]	Korea	retrospective study	143	101	42	57(20-82）	Ultravist	2mL/kg	Histopathologic examination
Liang 2021 [8]	China	retrospective study	125	79	46	53.6±11.9	Onepike	300mg/ml	Histopathologic examination
Hu 2014 [22]	China	retrospective study	117	71	46	NA	Iohexol	80mL	Histopathologic examination
Pei 2010 [23]	China	retrospective study	50	32	18	53.26±11.5	Iohexol	1.5mL/kg	Histopathologic examination
Zhu 2017 [24]	China	retrospective study	52	34	18	NA	Iohexol	80mL	Histopathologic examination
Qu 2023 [25]	China	retrospective study	81	44	37	60 (37-83)	Iohexol	80mL-100mL	Histopathologic examination
Li 2023 [26]	China	retrospective study	76	55	21	48.54±11.95	Iohexol	80mL-100mL	Histopathologic examination
Lu 2023 [27]	China	retrospective study	100	54	46	56.70±7.80	Iohexol	1.5mL/kg	Histopathologic examination
Qiao 2023 [28]	China	retrospective study	102	55	47	NA	Iopamidol	1.2mL/kg-1.5mL/kg	Histopathologic examination